04084nam 2200973z- 450 991036773760332120231214133235.03-03921-851-4(CKB)4100000010106341(oapen)https://directory.doabooks.org/handle/20.500.12854/53201(EXLCZ)99410000001010634120202102d2019 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierMERS-CoVMDPI - Multidisciplinary Digital Publishing Institute20191 electronic resource (274 p.)3-03921-850-6 Middle East respiratory syndrome coronavirus (MERS-CoV) is an emerging zoonotic coronavirus. First identified in 2012, MERS-CoV has caused over 2460 infections and a fatality rate of about 35% in humans. Similar to severe acute respiratory syndrome coronavirus (SARS-CoV), MERS-CoV likely originated from bats; however, different from SARS-CoV, which potentially utilized palm civets as its intermediate hosts, MERS-CoV likely transmits to humans through dromedary camels. Animal models, such as humanized mice and nonhuman primates, have been developed for studying MERS-CoV infection. Currently, there are no vaccines and therapeutics approved for the prevention and treatment of MERS-CoV infection, although a number of them have been developed preclinically or tested clinically. This book covers one editorial and 16 articles (including seven review articles and nine original research papers) written by researchers working in the field of MERS-CoV. It describes the following three main aspects: (1) MERS-CoV epidemiology, transmission, and pathogenesis; (2) current progress on MERS-CoV animal models, vaccines, and therapeutics; and (3) challenges and future prospects for MERS-CoV research. Overall, this book will help researchers in the MERS-CoV field to further advance their work on the virus. It also has important implications for other coronaviruses as well as viruses outside the coronavirus family with pandemic potentials.cell–cell fusionhDPP4n/atherapeuticsanimal modelsHCoV-229EDriverscamelsrabbitsSARS-CoVMERS-CoVMVA vaccinetransmissionRBDMERS-CoV nucleocapsid proteincomplementanimal modelpseudotyped viruscombinationMERS-coronaviruspeptidemouse modelspike proteinreceptor-binding domainprevention and treatmentcoronavirusescoronavirus spike glycoproteintherapeutic antibodiesvaccine platformsmutationsevere acute respiratory syndrome coronaviruspathogenesisfusion inhibitorCoronavirusmurine CD8+ T cell epitopelipidomicsauthentic viruscorrelates of immunityvaccinesneutralizing monoclonal antibodiesMiddle East respiratory syndrome coronavirussmall-molecule inhibitorMiddle East Respiratory Syndrome VirusDPP4pyroptosiscross-neutralizationinflammationQatarspike proteinsOne HealthHKU4nanobodiesmechanism of actionneutralizing antibodyhost factorsUHPLC–MSDu Lanyingauth1322339Li FangauthBOOK9910367737603321MERS-CoV3034884UNINA